Medication info
Lozatine Plus F Tablet

Lozatine Plus F Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200607958 · Notified 2006.10.16 · Insurance code 647300250

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medication is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medication may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medication when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Combination therapy with individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medication. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. For patients with more severe renal impairment, loop diuretics are preferable to thiazide drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medication cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dosage adjustment.
Child dose
Under 18 years: Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medication is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medication may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medication when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Combination therapy with individually adjusted doses of losartan potassium and hydrochlorothiazide may be replaced with this medication. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. For patients with more severe renal impairment, loop diuretics are preferable to thiazide drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medication cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dosage adjustment.

Child dose

Under 18 years: Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. Use should be avoided in patients with certain allergic reactions or severely impaired kidney function, severely compromised liver function, and those with certain genetic metabolic disorders. Caution should be taken when administering this medication to patients with low blood pressure or dehydration, renal or liver issues, and electrolyte imbalances such as hyperkalemia or hypokalemia. As this medication lowers blood pressure, dizziness or drowsiness may occur at the beginning of treatment or when the dosage is increased. The hydrochlorothiazide component can cause electrolyte imbalances, so regular blood tests should be performed to monitor electrolyte levels. This medication may increase sensitivity to sunlight, so it is important to avoid prolonged exposure to ultraviolet light, and to consult a doctor immediately if any skin abnormalities occur. During treatment with this medicine, potassium supplements or potassium-containing salt substitutes should not be taken without consulting a physician. This medication may interact with other antihypertensive medications or specific drugs, so it is essential to inform healthcare providers of any other medications being taken. Safety and efficacy have not been established for use in children or adolescents. It is important to consult healthcare providers immediately if any abnormal symptoms or discomfort occur during treatment.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 129 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin exfoliation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory disturbance
  • insomnia
  • reduced libido
  • memory impairment
  • migraine
  • hyperesthesia
  • panic disorder
  • paresthesia
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • spasm
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle twitching
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • yellow vision
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it should be stored at room temperature, specifically between 1°C and 30°C, to maintain its efficacy and safety.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.